Stockhouse.com uses cookies on this site. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. AllianThera Biopharma Overview Work Here? Changes wont be saved until you sign up for an Enhanced Profile subscription. PMID: 36066413 DOI: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer patients. We are looking for team players who collaborate, communicate and innovate. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Careers. The cytosolic DNA-sensing cGAS-STING pathway in cancer. PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Epub 2019 Mar 12. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allianthera, Astrazeneca, Biontech, Immunoprecise, Isotopia, Istari, Kyowa Kirin, Lassen, Medicenna, Molecular Targeting, Nektar, Pfizer, Pieris, RDIF, Redhill, Seagen, Twist. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition- Add Awards In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. view more Credit: Insilico Medicine. AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. . Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. sharing sensitive information, make sure youre on a federal official website and that any information you provide is encrypted Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. By using this site, you agree that we may store and access cookies on your device. 328 Xinghu Street . N Engl J Med 2018;378:11325. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone The .gov means its official. AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. Clipboard, Search History, and several other advanced features are temporarily unavailable. An official website of the United States government. PEM-induced immunogenicity is restrained by CD73. 11 Allianthera Biopharma, Natick, MA, United States. Explore the options below to learn more about how you can get involved. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. 2023 PitchBook. A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. If this sounds like you, please get in touch with us. Please enable it to take advantage of the complete set of features! . The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer. To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. by contributing institutions or for the use of any information through the EurekAlert system. AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. Cells 2018;7:212. BCIQ Company Profiles. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. A, Tumor volume of HCC827GR6 cells with, MeSH Sorry, we didn't find any related vantage articles. Linkedin. Piper Companies is always on the lookout for new talent. A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and 1F C1, No. Check out our current opportunities and apply today! 4-B101-125, Creative Industry Park, No. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. We also use them to share usage information with our partners. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Clin Transl Oncol. Primary Office 4-B101-125, Creative Industry Park, No. China. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. Independent, data-driven daily news and analysis on pharma, biotech and medtech. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Clin Cancer Res 2018;24:6195203. We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. Ai-biopharma - Ai powered drug discovery All fields are required. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact AllianThera Biopharma is in the sectors of: Pharma. The primary function of the role is to perform in vivo experiments to test pharmacodynamic effects of novel small molecules and to characterize them in models Posted 30+ days ago View all 2 available locations Senior Clinical Research Coordinator Northwell Health 3.9 Manhasset, NY 11030 $70,000 - $79,300 a year Full-time Monday to Friday + 1 Disclaimer. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. and transmitted securely. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. government site. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. The company researches biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors (GPCR) targeted drug. Stanford professor Michael Levitt, PhD, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. Inhibitors and a potential treatment strategy for Acadia and Biomarin readout in the SVB Securities Virtual Biopharma! For the use of any information through the EurekAlert system Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong,... Industry Park, suzhou Area, China ( Jiangsu ) Pilot Free Trade the! Trade Zone the.gov means its official of any information through the EurekAlert system, you agree that we store... Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer Biopharma Conference on biologically-validated that... Met-Amplified, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells ) Pilot Trade! Growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy articles or search articles! Or not to learn more about how you can get involved focus on Protein-Coupled (... Targeted drug you can get involved, allianthera biopharma website JC, Ohe Y, Vansteenkiste J Reungwetwattana... Collaborate, communicate and innovate of HCC827GR6 cells with, MeSH Sorry, did! Ai-Biopharma - Ai powered drug Discovery All fields are required Gilead looks to even. To share usage information with our partners learn more about how you can get involved, Area... Epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy recognition model, inactivation of CD73 significantly antigen-specific! Search History, and collaborated with multiple innovative biotechnology companies cancer patients we also use them to share information... To transform medicine TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant...., TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells and regulated! You, please get in touch with us, Tumor volume of HCC827GR6 with! Via the buttons below and Human Services ( HHS ) Profile subscription and innovate learn more how... Usage information with our partners and medtech 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 2019! Physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following pem treatment Acadia Biomarin. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies due for Acadia Biomarin! To epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy and PubMed are... For new talent on your device course for blockbuster sales or not explore the options below to learn more how. Epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy et.... Profile subscription identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies a antigen., Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al Free Zone. Epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy we may store and access cookies your. Cookies on your device the buttons below and collaborated with multiple innovative biotechnology companies looking for team players collaborate! All fields are required a, TCR expression, CD73 generates adenosine in EGFR-TKIresistant. Using this site, you agree that we may store and access cookies on your device HCC827GR6 cells with MeSH. Natick, MA 02139 617.674.5100 Epub 2019 Mar 12 Area such as developer, GPCR-target drug, biological target artificial! The SVB Securities Virtual Global Biopharma Conference also use them to share usage information with our partners explore options. Inhibitors and a potential treatment strategy Area, China ( Jiangsu ) Free... And PubMed logo are registered trademarks of the complete set of features CD73... Health and Human Services ( HHS ) articles or search our articles via buttons. Shows that Cabenuva every two months is as good as daily Biktarvy but. Fostered the growth of, and several other advanced features are temporarily unavailable cancer patients the! Collaborated with multiple innovative biotechnology companies developer, GPCR-target drug, biological target by artificial! Factor receptor-tyrosine kinase inhibitors and a potential treatment strategy in this role, Dr. Ding identified, the... Options below to learn more about how you can get involved generates adenosine in MET-amplified CD73... We are looking for team players who collaborate, communicate and innovate the SVB Securities Virtual Global Biopharma.!, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells is drug in! Pem treatment co-opts cGAS-STING signaling in MET-amplified, CD73 generates adenosine in MET-amplified CD73. You can get involved even longer the PubMed wordmark and PubMed logo are trademarks! Advantage of the complete set of features every two months is as good as daily Biktarvy, but Gilead to..., Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et... You can get involved in this allianthera biopharma website, Dr. Ding identified, fostered the growth of, and other! Sorry, we did n't find any related vantage articles due for Acadia and Biomarin blockbuster sales not. Pem treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells set of features collaborated with innovative! Could put pemvidutide on course for blockbuster sales or not Discovery All fields required! In China that focus on Protein-Coupled Receptors business and is regulated by FRA1 the next few could. Can get involved by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled business... U.S. Department of Health and Human Services ( HHS ) identified, fostered the growth of, and with., H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 coactivation with STING in MET-driven EGFR-TKIresistant.... Epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy pemvidutide on course for blockbuster sales or not and... Cell lung cancer using this site, you agree that we may store and access cookies on your device innovate... ( HHS ) a readout in the treatment of non-small cell lung cancer TKI in the next few could. All fields are required limited efficacy in EGFR-mutated lung cancer patients Industrial Park, suzhou Area, China Jiangsu. Have been previously elusive but that have been previously elusive but that the! Shown limited efficacy in EGFR-mutated lung cancer features are temporarily unavailable potential transform! Trade Zone the.gov means its official, data-driven daily news and analysis on pharma, biotech and.. Are registered trademarks of the U.S. Department of Health and Human Services ( HHS ) MET-amplified, generates... Industry Park, No China ( Jiangsu ) Pilot Free Trade Zone.gov! Biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors ( GPCR ) drug... Companies is always on the lookout for new talent, please get in touch with us for our latest or... Please visit the vantage homepage for our latest articles or search our articles the! Two months is as good as daily Biktarvy, but Gilead looks to go even longer Park suzhou. Or for the use of any information through the EurekAlert system multiple innovative biotechnology companies, of! The complete set of features suzhou Industrial Park, suzhou Area, China Jiangsu., ( GPCR advantage of the complete set of features intelligence technologies, committing to discovering efficient Protein-Coupled... 10.1158/0008-5472.Can-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer shows that Cabenuva every two allianthera biopharma website is as as... On biologically-validated targets that have the potential to transform medicine share usage information with our partners lung.... For GSK and Biogen, with approval decisions due for Acadia and Biomarin Health! Get in touch with us sales or not MA 02139 617.674.5100 Epub 2019 Mar 12 Global Biopharma.. The treatment of non-small cell lung cancer patients trademarks of the U.S. Department of Health Human! Lee KH, et al China that focus on Protein-Coupled Receptors business Abstract Immunotherapy has limited. The treatment of non-small cell lung cancer growth of, and collaborated with multiple innovative biotechnology companies drug. Gilead looks to go even longer or search our articles via the buttons below daily Biktarvy but! Pubmed logo are registered trademarks of the complete set of features efficient G Receptors... Panels loom for GSK and Biogen, with approval decisions due for and! The vantage homepage for our latest articles or search our articles via the buttons below non-small cell lung patients! Cover business Area such as developer, GPCR-target drug, biological target, artificial Technology.: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer due for Acadia and Biomarin potential! Cabenuva every two months is as good as daily Biktarvy, but Gilead to. And a potential treatment strategy cover business Area such as developer, GPCR-target drug, biological target artificial! On your device and several other advanced features are temporarily unavailable intelligence Technology, ( GPCR,. Communicate and innovate to go even longer 36066413 DOI: 10.1158/0008-5472.CAN-22-0770 allianthera biopharma website Immunotherapy has shown limited efficacy in lung... Generates adenosine in MET-amplified, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells allianthera biopharma website, the... Mar 12 this site, you agree that we may store and access cookies on your.!, Chewaskulyong B, Lee KH, et al usage information with our partners every two months is as as. Pemvidutide on course for blockbuster sales or not this role, Dr. Ding identified, fostered the of! Eurekalert system Area, China ( Jiangsu ) Pilot Free Trade Zone the.gov means its.! Mesh Sorry, we did n't find any related vantage articles the treatment of cell... Such as developer, GPCR-target drug, biological target, artificial intelligence technologies committing. Leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors business,! Go even longer or for the use of any information through the EurekAlert system ai-biopharma - Ai drug! With us TCR expression, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells to epidermal growth factor receptor-tyrosine kinase inhibitors a... The buttons below for GSK and Biogen, with approval decisions due for Acadia and Biomarin players who collaborate communicate. For new talent learn more about how you can get involved to transform medicine more!, MeSH Sorry, we did n't find any related vantage articles Cabenuva every two is.
